These results suggest that CD4+ T cells improve oncolytic virus-induced anti-tumor immunity by amplifying tumor-specific CD8+ T cell activation and could be beneficial in the context of suboptimal induction of anti-tumor CD8+ T cells, despite being dispensable in this setting of potently primed CD8+ T cells. This evidence concerns the gene CD8A and neoplasm.